Lion Point Capital’s Jasper Therapeutics JSPR Stock Holding History

Lion Point Capital’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$407K	Hold	465,000	–	–	2.44%	16
2025 Q4	$851K	Buy	465,000 +66,442	+17%	+$133K	4.4%	5
2025 Q3	$949K	Buy	398,558 +252,058	+172%	+$764K	5.39%	4
2025 Q2	$813K	Hold	146,500	–	–	5.52%	9
2025 Q1	$630K	Buy	146,500 +114,500	+358%	+$762K	4.02%	12
2024 Q4	$684K	Hold	32,000	–	–	3.58%	12
2024 Q3	$602K	Hold	32,000	–	–	1.34%	17
2024 Q2	$726K	Hold	32,000	–	–	1.32%	17
2024 Q1	$940K	Buy	+32,000	New	+$568K	0.53%	17

Other funds holding JSPR

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Lion Point Capital's JSPR Position: Q1 2026 in Review

Lion Point Capital held its Jasper Therapeutics (JSPR) position steady in Q1 2026 at 465,000 shares worth $407K. The position accounts for 2.44% of the portfolio, ranked #16.

Lion Point Capital first reported a position in JSPR in Q1 2024 and has held it in 9 quarters since. The position peaked at $949K in Q3 2025. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

Lion Point Capital held 465,000 shares of Jasper Therapeutics worth $407K as of Q1 2026.
Lion Point Capital left its Jasper Therapeutics share count unchanged in Q1 2026.
Jasper Therapeutics made up 2.44% of Lion Point Capital's portfolio in Q1 2026, its #16 holding.
Lion Point Capital first reported a position in Jasper Therapeutics in Q1 2024 and has held it in 9 quarters since.
Lion Point Capital's Jasper Therapeutics position peaked at $949K in Q3 2025.
58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on Lion Point Capital's 13F filing for Q1 2026, filed 15 May 2026.